The effect of the oral oxytocin antagonist, nolasiban, on pregnancy rates in women undergoing embryo transfer following IVF

Georg Griesinger, MD, PhD; Jacques Donnez, PhD, MD; Andrew Humberstone, PhD; Paul Terrill, PhD; Oliver Pohl, DVM, MPH, MSc; Elizabeth Garner, MD, MPH; Ernest Loumaye, MD, PhD

ASRM 2020 Virtual Congress, October 2020

Poster session, abstract – Poster P. 482, page e303

Fertility and Sterility, Volume 114, No. 3, Supplement, September 2020, Poster P-482, page e303

Efficacy and safety of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids: Results from two Phase 3 randomized clinical trials

Elizabeth A. Stewart, MD; Hugh S. Taylor, MD; Robert N. Taylor, MD, PhD; Jacques Donnez, PhD, MD; Elke Bestel, MD; Jean-Pierre Gotteland, PhD; Andrew Humberstone, PhD; Elizabeth Garner, MD, MPH

ASRM 2020 Virtual Congress, October 2020

Poster session, Late-breaking abstract – Poster P. 930, page e527

Fertility and Sterility, Volume 114, No. 3, Supplement, September 2020, Poster session, Late-breaking abstract – Poster P. 930, page e527

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue